The company stated: “By streamlining our operations and removing the reimbursement volatility associated with Resolve, we are effectively resetting our growth trajectory for the remainder of the year. We are establishing updated 2026 revenue guidance for our core cancer business, now excluding Resolve, of $110-115 million, which would represent 20-26% year-over-year growth over our 2025 core cancer business.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- Mdxhealth Exits Resolve Business, Refocuses on Prostate Cancer as Q1 2026 Revenue Rises 13%
- MDxHealth reports Q1 EPS (17c) vs. (19c) last year
- Mdxhealth S.A. (MDXH) Q1 Earnings Cheat Sheet
- MDxHealth Sets May 28, 2026 Shareholders’ Meetings to Approve 2025 Accounts and Governance Moves
- MDxHealth management to meet virtually with Willlam Blair